Navigation Links
Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections

A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.

The team studied patients infected with the fungus Candida albicans (C. albicans), which causes common yeast infections and more serious bloodstream infections, who were being treated with fluconazole, one of the primary anti-fungal drugs now in use. They found that the fungus undergoes 240 genetic changes associated with drug resistance. But those changes come with a cost, they discovered. As it battles to overcome the effects of the drug, the fungus becomes weaker, with a reduction in the traits associated with virulence. The discoveries may point toward new targets for research and the potential to develop new classes of therapeutics for hard-to-treat fungal infections.

The project was co-directed by Reeta Rao, PhD, associate professor of biology and biotechnology at WPI; Dawn Thompson, PhD, and Aviv Regev, PhD, of the Broad Institute of MIT and Harvard; and Judith Berman, PhD, of Tel Aviv University. They report their findings in the paper “The evolution of drug resistance in clinical isolates of Candida albicans,” published by the open-access journal eLife.

“Virtually all humans are colonized with Candida albicans, but in some individuals this benign organism becomes a serious, life-threatening pathogen,” the team wrote. “Here, we used genome sequencing of isolates sampled consecutively from patients that were clinically treated with fluconazole to systematically analyze the genetic dynamics that accompany the appearance of drug resistance during oral candidiasis [infection]. Most of the genes in these clusters are not well characterized and represent new candidates involved (in) drug resistance and adaptation to the host environment.”

In an accompanying eLife “Insight” piece commenting on the importance of the C. albicans drug resistance study, two researchers from the École Polytechnique Fédérale in Lausanne, Switzerland, wrote: “The work provides a global description of the genetic processes underlying drug resistance and adaptation in C. albicans. Of note, all sequencing data have been made publicly available, which is an unprecedented resource for the research community.”

Thrush and vaginitis, common yeast infections caused by C. albicans, typically do not cause serious harm, but can become chronic due to a lack of drugs that can completely clear the pathogen. If a fungal infection spreads to the bloodstream (for example, via catheters or central intravenous lines), it can be deadly. Patients with compromised immune systems or implanted medical devices like pacemakers or prosthetic hips or knees, are also at greater risk for serious systemic fungal infections, which have a mortality rate between 30 and 50 percent.

In the current study, researchers sequenced the DNA and tested samples of C. albicans collected from patients with HIV who also had thrush and were being treated with fluconazole. The “azole” family of drugs do not kill the fungi—they limit growth by disrupting a protein in the yeasts’ outer membrane. In many cases, some C. albicans organisms overcome the effects of fluconazole and continue to cause an infection.

Using next-generation DNA sequencing technology, the team looked for changes at the genetic level in 43 samples of C. albicans collected from the 11 patients over ten months. By sampling fungi from the same patients over time, researchers identified genetic mutations that correlated with the fungi’s evolving ability to overcome the effects of fluconazole in those patients. The results revealed changes in genes associated with the structure of fungi’s outer membrane and the activity of molecular pumps that can eject the drug from the yeast’s cells. Numerous other genetic mutations were found to be prevalent as drug resistance increased, though the functional impact of those changes is not known.

The DNA sequencing and genomic analysis was done at the Broad Institute and Tel Aviv University. At WPI, Rao’s lab tested the fitness and virulence of the C. albicans strains in the 43 samples. Those experiments found an inverse relationship between increased drug resistance and the ability of C. albicans to survive or cause additional infection. “At first that may seem counterintuitive, but it’s actually a logical finding,” Rao said. “It shows there is a fitness cost involved in overcoming the effect of the drug. C. albicans devotes more energy to battling the drug, so it becomes less fit and unable to cause infection until it has figured out how to overcome the effect of the drug.”

Studying that window of vulnerability, when the fungus is weaker and less likely to cause more infection but not fully resistance to the drug, becomes an interesting opportunity to explore, Rao noted. Also, much more work is needed to understand the specific impact of the 240 genetic mutations found to be associated with drug resistance. Furthermore, understanding how C. albicans evades fluconazole may shed light on how some cancer cells develop resistance to current therapies because “the evolution of drug resistance in C. albicans has many parallels with the somatic evolution of cancer cells undergoing chemotherapy or treated with specific inhibitors,” the authors wrote.

About Worcester Polytechnic Institute

Founded in 1865 in Worcester, Mass., WPI is one of the nation’s first engineering and technology universities. Its 14 academic departments offer more than 50 undergraduate and graduate degree programs in science, engineering, technology, business, the social sciences, and the humanities and arts, leading to bachelor’s, master’s and doctoral degrees. WPI's talented faculty work with students on interdisciplinary research that seeks solutions to important and socially relevant problems in fields as diverse as the life sciences and bioengineering, energy, information security, materials processing, and robotics. Students also have the opportunity to make a difference to communities and organizations around the world through the university's innovative Global Perspective Program. There are more than 40 WPI project centers in the Americas, Africa, Asia-Pacific, and Europe.

Michael Cohen
508-868-4778, mcohen(at)wpi(dot)edu
# # #

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin
2. Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies
3. Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats
4. AbbVie Announces Inaugural Week of Possibilities Volunteer Program to Support Six Schools in North Chicago, Ill., and Worcester, Mass.
5. Worcester Polytechnic Institute Receives NIH Grant to Study Components of a Potentially Potent and Cost-Effective Malaria Treatment
6. Worcester Polytechnic Institute’s Tanja Dominko Named Slovenian Ambassador of Science for 2013
7. Averica Discovery Services and Worcester Polytechnic Institute Establish Research Collaboration
8. Broad Institute, Google Genomics combine bioinformatics and computing expertise to expand access to research tools
9. Philanthropists unite to accelerate global fight against tuberculosis with combined $20 million gift to Broad Institute
10. Metabolic Medical Institute Announces GWU Masters Program in Integrative Medicine
11. QIAGEN and Inova Translational Medicine Institute Introduce New Database of Ethnically and Phenotypically Diverse Whole Genome Information
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
Breaking Biology News(10 mins):